AstraZeneca issues 11,948 employee scheme shares

Following the admission, AstraZeneca had 1,551,065,237 securities in issue.

Available on EDGAR 11/02/2026 - 10:32 AM EST Accepted by SEC EDGAR 11/02/2026 - 10:32 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

AstraZeneca PLC issued and admitted 11,948 ordinary shares of $0.25 each to trading on the London Stock Exchange Main Market under its employee share schemes between October 1 and October 31, 2026. The shares were admitted under the existing block admission dated January 29, 2021, and are fully fungible with existing ordinary shares. Total securities in issue following admission were 1,551,065,237.

Key Figures

Further ordinary shares issued and admitted: 11,948 shares Total securities in issue: 1,551,065,237 securities Nominal value: $0.25 per ordinary share

3 metrics

Further ordinary shares issued and admitted 11,948 shares Employee share schemes; October 1–31, 2026

Total securities in issue 1,551,065,237 securities Following admission

Nominal value $0.25 per ordinary share Ordinary Shares

Key Terms

block admission, fungible, employee share schemes

3 terms

block admission technical

"existing block admission of shares dated January 29, 2021"

fungible financial

"Fully fungible with existing Ordinary Shares"

Fungible describes an asset that is interchangeable with another of the same kind because each unit holds the same value and function. For investors this matters because fungible assets are easier to trade, price, and store—think of cash or grains where one unit can replace another, unlike a unique artwork or a signed collectible which may be worth more or less depending on provenance. Fungibility affects liquidity, market efficiency, and how assets are settled or regulated.

employee share schemes financial

"Admission of shares under the Company’s employee share schemes"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AZN shares were admitted to trading?

AstraZeneca issued and admitted 11,948 ordinary shares to trading between October 1 and October 31, 2026, under its employee share schemes. The shares were admitted under the existing block admission dated January 29, 2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1. Admission of Further Securities to Trading

2 November 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	11,948
d)	Total number of securities in issue following admission	1,551,065,237
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 1 October 2026 to 31 October 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company’s employee share schemes from 1 October 2026 up to 31 October 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company’s existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 02 November 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary